Shire (NASDAQ:SHPG) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a note issued to investors on Tuesday, February 6th.
According to Zacks, “The sales of Mydayis did not meet Shire’s expectation while strong performance of Vyvanse, Cinryze and Elaprase continue to drive Shire’s top line. The label expansion of Cinryze in paediatrics and conditional approval of Natpara in Europe should continue to drive the top line going ahead. The hematology and immunology segment, acquired from Baxalta, gave a major boost to product sales. The approval of Xiidra has boosted the company’s ophthalmology portfolio. However, the adult ADHD space is one of the largest and fastest growing segments of the market but is highly genericized. Supply shortage for Cinryze and generic competition for Lialda had an unfavorable impact on the top line. Moreover, its shares have underperformed the industry in the past one year. Estimates have increased ahead of the Q4 earnings results. The company has a positive record of earnings surprises in recent quarters.”
A number of other equities research analysts have also issued reports on SHPG. ValuEngine lowered shares of Shire from a “buy” rating to a “hold” rating in a report on Friday, February 2nd. FBR & Co started coverage on shares of Shire in a report on Thursday, October 19th. They set a “buy” rating and a $201.00 target price on the stock. Cantor Fitzgerald set a $222.00 target price on shares of Shire and gave the stock a “buy” rating in a report on Thursday, November 16th. Royal Bank of Canada reiterated a “buy” rating on shares of Shire in a report on Thursday, November 16th. Finally, Liberum Capital upgraded shares of Shire from a “hold” rating to a “buy” rating in a report on Tuesday, November 14th. One investment analyst has rated the stock with a sell rating, eight have given a hold rating and ten have issued a buy rating to the company. The stock currently has a consensus rating of “Hold” and a consensus target price of $212.50.
Shire (NASDAQ:SHPG) last issued its quarterly earnings data on Wednesday, February 14th. The biopharmaceutical company reported $3.98 EPS for the quarter, topping the consensus estimate of $3.86 by $0.12. Shire had a net margin of 10.95% and a return on equity of 14.41%. The firm had revenue of $4.15 billion for the quarter. During the same quarter in the prior year, the company posted $3.37 earnings per share. The business’s revenue was up 8.9% compared to the same quarter last year. research analysts anticipate that Shire will post 15 earnings per share for the current year.
Several hedge funds and other institutional investors have recently bought and sold shares of the stock. Harding Loevner LP grew its position in shares of Shire by 18,894.4% in the 3rd quarter. Harding Loevner LP now owns 127,537,052 shares of the biopharmaceutical company’s stock valued at $20,354,000 after buying an additional 126,865,607 shares during the last quarter. Boston Partners grew its position in shares of Shire by 60.9% in the 4th quarter. Boston Partners now owns 2,342,391 shares of the biopharmaceutical company’s stock valued at $363,351,000 after buying an additional 886,572 shares during the last quarter. Janus Henderson Group PLC grew its position in shares of Shire by 35.3% in the 3rd quarter. Janus Henderson Group PLC now owns 1,740,973 shares of the biopharmaceutical company’s stock valued at $266,613,000 after buying an additional 454,092 shares during the last quarter. Ameriprise Financial Inc. grew its position in shares of Shire by 6.4% in the 3rd quarter. Ameriprise Financial Inc. now owns 1,606,342 shares of the biopharmaceutical company’s stock valued at $245,997,000 after buying an additional 96,115 shares during the last quarter. Finally, Third Point LLC purchased a new position in shares of Shire in the 3rd quarter valued at $183,768,000. 20.74% of the stock is currently owned by hedge funds and other institutional investors.
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Shire Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire and related companies with MarketBeat.com's FREE daily email newsletter.